{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:32:23Z","timestamp":1762954343167},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1016\/j.eururo.2003.09.013","type":"journal-article","created":{"date-parts":[[2003,10,11]],"date-time":"2003-10-11T02:52:31Z","timestamp":1065840751000},"page":"142-146","source":"Crossref","is-referenced-by-count":78,"title":["Bladder Carcinoma in Situ in 2003: State of the Art"],"prefix":"10.1016","volume":"45","author":[{"given":"J.A.","family":"Witjes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2003.09.013_BIB1","first-page":"147","article-title":"Natural history of carcinoma in situ of the urinary bladder","volume":"157","author":"Wolf","year":"1994","journal-title":"Scand J. Urol. Nephrol. Suppl."},{"key":"10.1016\/j.eururo.2003.09.013_BIB2","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol. Clin. North Am"},{"key":"10.1016\/j.eururo.2003.09.013_BIB3","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0090-4295(98)00374-4","article-title":"Microstaging of pT1 transitional cell carcinoma of the bladder, identification of subgroups with distinct risks for progression","volume":"52","author":"Smits","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2003.09.013_BIB4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","article-title":"Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance","volume":"167","author":"Griffiths","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00000478-200103000-00010","article-title":"Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion","volume":"25","author":"McKenney","year":"2001","journal-title":"Am J. Surg. Pathol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0022-5347(17)50195-0","article-title":"Upper urinary tract transitional cell cancer after radical cystectomy for bladder cancer","volume":"131","author":"Zincke","year":"1984","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(01)69073-6","article-title":"Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder","volume":"167","author":"Nixon","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0302-2838(02)00006-4","article-title":"Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis","volume":"41","author":"Raitanen","year":"2002","journal-title":"Eur. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0090-4295(02)02136-2","article-title":"Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses","volume":"61","author":"Lotan","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2003.09.013_BIB10","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/01.ju.0000048983.83079.4c","article-title":"Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study","volume":"169","author":"Pfister","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow up cystoscopy after TUR in stage TaT1 transitional cell carcinoma of the bladder: a combined analysis of 7 EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB12","unstructured":"Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate (HAL) fluorescence cystroscopy. Submitted."},{"key":"10.1016\/j.eururo.2003.09.013_BIB13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0302-2838(02)00402-5","article-title":"Fluorescence detection of bladder cancer: a review","volume":"42","author":"D\u2019Hallewin","year":"2002","journal-title":"Eur. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","article-title":"Guidelines on bladder cancer","volume":"41","author":"Oosterlinck","year":"2002","journal-title":"Eur. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB15","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB16","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0022-5347(05)66333-1","article-title":"Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and\/or high grade bladder tumors","volume":"165","author":"Palou","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB17","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0022-5347(01)69072-4","article-title":"Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup","volume":"167","author":"Davis","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB19","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","article-title":"Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial","volume":"13","author":"Herr","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.eururo.2003.09.013_BIB20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1569-9056(03)80754-6","article-title":"Comparison of a standard BCG dose (81 mg) versus a three-fold reduced dose (27 mg) in high risk superficial bladder cancer (T1G3, TIS). A Cueto prospective randomised study #95012","volume":"2","author":"Martinez Pineiro","year":"2003","journal-title":"Eur. Urol. Suppl."},{"issue":"1","key":"10.1016\/j.eururo.2003.09.013_BIB21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1569-9056(03)80753-4","article-title":"Maintenance bacillus Calmette-Guerin for Ta, T1 bladder cancer is not associated with increased toxicity. Results from an EORTC Genito-Urinary group phase III trial","volume":"2","author":"van der Meijden","year":"2003","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.eururo.2003.09.013_BIB22","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0022-5347(01)62377-2","article-title":"Results of a randomized phase III trial of sequential intravesical therapy with Mitomycin-C and bacillus Calmette-Guerin versus Mitomycin-C alone in patients with superficial bladder cancer","volume":"160","author":"Witjes","year":"1998","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB23","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB25","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O\u2019Donnell","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0090-4295(02)02123-4","article-title":"Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study","volume":"61","author":"Berger","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2003.09.013_BIB27","unstructured":"Schrier BPH, Hollander MP, van Rhijn BWG, Ijzer S, Kiemeney LALM, Witjes JA. Prognosis of muscle invasive bladder cancer: difference between primary and progressive tumors: possible implications for therapy, Submitted."},{"key":"10.1016\/j.eururo.2003.09.013_BIB28","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1097\/01.ju.0000043638.89552.ed","article-title":"Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder","volume":"169","author":"Shariat","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/bjc.1995.40","article-title":"Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer","volume":"71","author":"Ravery","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.eururo.2003.09.013_BIB30","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1159\/000020364","article-title":"p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?","volume":"38","author":"Schmitz-Drager","year":"2000","journal-title":"Eur. Urol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB31","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0090-4295(03)00236-X","article-title":"Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder","volume":"61","author":"Shariat","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2003.09.013_BIB32","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0002-9440(10)64388-X","article-title":"Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma","volume":"161","author":"Hopman","year":"2002","journal-title":"Am J. Pathol."},{"key":"10.1016\/j.eururo.2003.09.013_BIB33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0090-4295(00)00892-X","article-title":"E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder","volume":"57","author":"Shariat","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2003.09.013_BIB34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0302-2838(01)00007-0","article-title":"Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer","volume":"41","author":"Kausch","year":"2002","journal-title":"Eur. Urol."}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283803004810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283803004810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T16:53:29Z","timestamp":1550681609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283803004810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["S0302283803004810"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2003.09.013","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}